

# Antimicrobial agents

# ANTIMICROBIAL AGENTS

- **Anti microbial agents:**
- includes **synthetic** as well as **naturally** obtained drugs that supress growth or kill microorganisms.

# classification

- Anti-bacterial.
- Anti-viral.
- Anti-fungal.
- Anti-parasitic agents.

# Mechanism of Action

- **Agents that inhibit synthesis of bacterial cell walls**

  - Penicillins & cephalosporins

  - Vancomycin

  - Azole antifungal agents (clotrimazole, fluconazole, itraconazole)

- **Agents that act directly on the cell membranes of the microorganisms**

Polyene antifungal agents

(Nystatin, Amphotericin B)

Alter cell memb. Permeability and lead to leakage of intracellular comp.

Gram-Positive Cocci		
<i>Streptococcus pneumoniae</i> <sup>7</sup> (pneumococcus)	Penicillin <sup>6</sup>	Macrolide, <sup>2</sup> a cephalosporin, <sup>8</sup> vancomycin, clindamycin, a tetracycline, <sup>3</sup> respiratory fluoroquinolones <sup>1</sup>
<i>Streptococcus</i> , hemolytic, groups A, B, C, G	Penicillin <sup>6</sup>	Macrolide, <sup>2</sup> a cephalosporin, <sup>8</sup> vancomycin, clindamycin
Viridans streptococci	Penicillin <sup>6</sup> ± gentamicin	Cephalosporin, <sup>8</sup> vancomycin
<i>Staphylococcus</i> , methicillin-resistant	Vancomycin	TMP-SMZ, <sup>4</sup> doxycycline, minocycline, linezolid <sup>11</sup> , tedizolid <sup>11</sup> , daptomycin <sup>11</sup> , telavancin <sup>11</sup> , dalbavancin <sup>11</sup> , oritavancin <sup>11</sup> , ceftaroline
<i>Staphylococcus</i> , non-penicillinase-producing	Penicillin <sup>6</sup>	A cephalosporin, <sup>8</sup> clindamycin
<i>Staphylococcus</i> , penicillinase-producing	Penicillinase-resistant penicillin <sup>9</sup>	Vancomycin, a cephalosporin, <sup>8</sup> clindamycin, amoxicillin-clavulanic acid, ampicillin-sulbactam, piperacillin-tazobactam, TMP-SMZ <sup>4</sup>
<i>Enterococcus faecalis</i>	Ampicillin ± gentamicin <sup>10</sup>	Vancomycin ± gentamicin
<i>Enterococcus faecium</i>	Vancomycin ± gentamicin <sup>10</sup>	Linezolid, <sup>11</sup> quinupristin-dalfopristin, <sup>11</sup> daptomycin, <sup>11</sup> tigecycline, <sup>11</sup> tedizolid, <sup>11</sup> oritavancin <sup>11</sup>

Suspected or Proved Etiologic Agent	Drug(s) of First Choice	Alternative Drug(s)
<b>Gram-Negative Cocci</b>		
<i>Moraxella catarrhalis</i>	Cefuroxime, a fluoroquinolone <sup>1</sup>	Ceftriaxone, cefuroxime axetil, a macrolide, <sup>2</sup> a tetracycline, <sup>3</sup> amoxicillin-clavulanic acid, TMP-SMZ <sup>4</sup>
<i>Neisseria gonorrhoeae</i> (gonococcus)	Ceftriaxone plus azithromycin or doxycycline	Cefixime plus azithromycin or doxycycline <sup>5</sup>
<i>Neisseria meningitidis</i> (meningococcus)	Penicillin <sup>6</sup>	Ceftriaxone, ampicillin

- **Agents that affect the function of 30S or 50S ribosomal subunits to cause a reversible inhibition of protein synthesis**
- **Bacteriostatic drugs**  
Chloramphenicol, Tetracyclines,  
Erythromycin, Clindamycin.



- **Agents that bind to 30S ribosomal subunit & alter protein synthesis, which eventually leads to cell death**

## **Aminoglycosides**

- **Agents that affect bacterial nucleic acid metabolism.**

Rifamycins which inhibit RNA polymerase

Quinolones which inhibit topoisomerases

- Metronidazole diffuses into the organism, inhibits protein synthesis by interacting with DNA and causing a loss of helical DNA structure and strand breakage. Therefore, it causes cell death in susceptible organisms

*Bacteroides*, gastrointestinal strains

Metronidazole

Ampicillin-sulbactam, piperacillin-tazobactam, carbapenem

- **Anti-metabolites**  
including trimethoprim & sulphonamides


# Antiviral agents

- Nucleic acid analogues.
- Non-nucleoside reverse transcriptase inhibitors.
- Inhibitors of viral enzymes

**Figure 20.2 Major Action Modes of Antimicrobial Drugs.**

**1. Inhibition of cell wall synthesis:** penicillins, cephalosporins, bacitracin, vancomycin

**2. Inhibition of protein synthesis:** chloramphenicol, erythromycin, tetracyclines, streptomycin



**3. Inhibition of nucleic acid replication and transcription:** quinolones, rifampin

**5. Inhibition of essential metabolite synthesis:** sulfanamide, trimethoprim

# Type of action

Bacteriostatic Agents

**Bactericidal Agents**

# Bacteriostatic Agents

**Sulphonamides**

**Tetracyclines**

**Chloramphenicol**

**Erythromycin**

**Ethambutol**



# Bactericidal Agents

**Penicillins/Cephalosporins.**

**Aminoglycosides**

**Rifampin**

- **Isoniazid**
- **Pyrazinamide**

# Other bactericidal ab

**Cephalosporins**

**Vancomycin**

**Nalidixic acid**

**Ciprofloxacin**

**Metronidazole**

**& Cotrimoxazole**

# Successful Antimicrobial Therapy

- **Concentration:** site of infection  
Concentration should inhibit microorganisms  
simultaneously it should be below the level toxic to human beings.
- **Host Defences**  
Immunity intact - Bacteriostatic Agents  
Impaired immunity - Bactericidal Agents

# Factors to consider when prescribing an antibiotic

- Any history of allergy, toxicity?
- Is it appropriate for the spectrum I want to cover?
- What route of admin: oral or i.v?
- Any factors affecting absorption ?
- Is it going to reach the site of infection?
- Any drug interactions?
- Any serious toxicity eg, hepatic, renal?
- Does it need monitoring eg aminoglycosides, vancomycin, streptomycin?

# Effects of Combinations of Drugs


- **Synergism** occurs when the effect of two drugs together is greater than the effect of either alone
- **Antagonism** occurs when the effect of two drugs together is less than the effect of either alone

Pneumonia, acute, community-acquired, non-ICU hospital admission	Pneumococci, <i>M pneumoniae</i> , <i>Legionella</i> , <i>C pneumoniae</i>	Ceftriaxone, 1 g intravenously every 24 hours or ampicillin, 2 g intravenously every 6 hours) <b>plus</b> azithromycin, 500 mg intravenously every 24 hours; <b>or</b> a respiratory fluoroquinolone <sup>3</sup> alone
--	---	---



# Resistance

Figure 20.20 Bacterial Resistance to Antibiotics.







# **Prevention of drug resistance**

# Prevention drug resistance

- Use of AMAs should not be:
  - indiscriminate.
  - inadequate .
  - unduly prolonged.
- Use rapidly acting & narrow spectrum (Selective) AMA whenever possible.

# Prevention DRUG RESISTANCE

- **Combination AMA**
  - whenever prolonged therapy is undertaken.  
Tuberculosis, SABA
- Infection by organism notorious for developing resistance  
Staph, E. Coli, M. Tuberculosis must be **treated intensively**.

*Pseudomonas aeruginosa*

Piperacillin-tazobactam or ceftazidime or cefepime, or imipenem or meropenem or doripenem or aztreonam ± aminoglycoside<sup>12</sup>

Ciprofloxacin (or levofloxacin) ± piperacillin-tazobactam; ciprofloxacin (or levofloxacin) ± ceftazidime; ciprofloxacin (or levofloxacin) ± cefepime; ceftazidime-avibactam<sup>13</sup>; ceftolozane-tazobactam<sup>13</sup>

Cystitis	<i>Escherichia coli</i> , <i>Staphylococcus saprophyticus</i> , <i>Klebsiella pneumoniae</i> , <i>Proteus</i> species, other gram-negative rods or enterococci	Nitrofurantoin monohydrate macrocrystals 100 mg twice daily for 5–7 days (unless pregnant); fosfomycin 3 g orally as a single dose	Cephalexin, 0.5 g orally four times daily for 7 days, for uncomplicated cystitis. Due to increasing resistance, TMP-SMZ and fluoroquinolones should not be used as first-line therapy for empiric treatment
Pyelonephritis	<i>E coli</i> , <i>K pneumoniae</i> , <i>Proteus</i> species, <i>S saprophyticus</i>	Fluoroquinolones <sup>4</sup> for 7 days if prevalence of resistance among uropathogens is < 10%	TMP-SMZ, <sup>1</sup> one double-strength tablet twice daily for 7–14 days for susceptible pathogens. Oral beta-lactams are considered less effective

Pharyngitis	Group A streptococcus	Phenoxymethyl penicillin, 0.5 g orally four times daily, or amoxicillin, 0.5–1 g orally three times daily, for 10 days	For patients with history of mild penicillin allergy, cephalexin, 0.5 g orally four times daily for 10 days; for patients with more severe penicillin allergy, clindamycin, 300 mg orally four times daily for 10 days; or azithromycin, 500 mg on day 1 and 250 mg on days 2–5; or azithromycin for susceptible isolates
Otitis media	<i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , <i>Moraxella catarrhalis</i>	Amoxicillin, 0.5–1 g orally three times daily for 10 days	Augmentin, <sup>2</sup> 0.875 g orally twice daily; or cefuroxime, 0.5 g orally twice daily; or cefpodoxime, 0.2–0.4 g daily; or doxycycline, 100 mg twice daily
Acute sinusitis	<i>S pneumoniae</i> , <i>H influenzae</i> , <i>M catarrhalis</i>	Augmentin, <sup>2</sup> 0.875 g orally twice daily	For patients allergic to penicillin, doxycycline, 100 mg twice daily for 10 days, or secondarily, some fluoroquinolones <sup>5</sup> can be considered. Due to increasing resistance among pneumococci, monotherapy with a macrolide, a cephalosporin, or TMP-SMZ is not recommended

- Thank you